Assessments of healthcare value have largely focused on measuring outcomes of care at a given level of cost with less attention paid to appropriateness. However, understanding how appropriateness relates to outcomes and costs is essential to determining healthcare value.
T
he challenge of understanding value in healthcare is increasingly important for hospitals and providers pursuing patient-centered, high-quality care. Percutaneous coronary intervention (PCI) is one of the most commonly performed and highly scrutinized medical procedures in the United States, responsible for an estimated $25 billion in costs each year to the healthcare system. 1, 2 As a result, PCI has become the focus of numerous healthcare value initiatives. The Center for Medicare and Medicaid Services has included components of PCI in its hospital value-based purchasing program for acute myocardial infarction (AMI), as well as its recent bundled payments for care improvement initiative. 3 Corresponding initiatives in the private sector are also being enacted. [4] [5] [6] [7] Despite growing enthusiasm for these initiatives, most programs focused on procedures like PCI are currently limited by fundamental challenges with measurement of healthcare value. For instance, original definitions have considered healthcare value as outcomes achieved at a given level of cost. 8 This definition, however, does not explicitly account for whether the procedure provided would result in an expected benefit to the patient-a concept captured by measuring the appropriateness of a procedure for a given clinical scenario. This raises several potential concerns for a procedure like PCI that has variable appropriateness from its use in AMI, where it can be lifesaving, to its use in asymptomatic ischemia, where its clinical benefits are substantially lower. Therefore, to truly understand the healthcare value of PCI, one must consider the appropriateness of the procedure for a given patient, in addition to costs and patient outcomes. Yet, prior work in this area has understudied appropriateness in its assessments. In a large population of patients undergoing PCI in the Veterans Affairs Healthcare System, investigators reported variability in outcomes and costs across hospitals but did not assess appropriateness. 9, 10 In an analysis of the National Cardiovascular Data Registry CathPCI registry, appropriateness of PCI was found to be uncorrelated with procedural complications in the hospital; however, no examination of postdischarge outcomes or costs was performed. 11 In an Ontario-based study, the relationship between long-term outcomes and appropriateness in stable coronary artery disease patients was analyzed in patients managed with revascularization and medications, but healthcare costs were not assessed. 12 Understanding the relationship of appropriateness with outcomes and costs is essential because a PCI that is of less appropriateness is of lower value to the patient, regardless of the outcome or cost.
Accordingly, we simultaneously examined the interrelationships between these 3 domains of PCI careappropriateness, outcomes, and costs-in a large feefor-service (FFS) Medicare population in Michigan. We accomplished this by linking clinical data from a unique statewide registry to comprehensive administrative and payment data. 13 We calculated hospital-level measures of appropriateness, 90-day outcomes, and costs for PCI, and then correlated these measures to develop a more comprehensive view of healthcare value. Our findings have implications for policy makers and payers seeking to introduce healthcare value initiatives for PCI and similar procedures.
METHODS

Data Sources
We used 2 data sources that were part of the Michigan Value Partnerships, a regional quality improvement partnership between Blue Cross Blue Shield of Michigan and practitioners, physician organizations, and acute care hospitals in the state.
The first data source was the Blue Cross Blue Shield Cardiovascular Consortium (BMC2), a registry of all nonfederal PCI-capable hospitals in the state of Michigan with 47 participating centers.
14 Captured data include detailed patient and hospital characteristics, procedural findings, interventions, and outcomes based on prespecified data elements defined by the collaborative and the National Cardiovascular Data Registry. Numerous prior publications have used the BMC2 PCI registry, including reports documenting the assessment of appropriateness and outcomes. A careful and detailed audit of this data source has been maintained for ≈2 decades. 15, 16 The second data source involved the Michigan Value Collaborative (MVC), a statewide quality improvement collaborative also funded by Blue Cross Blue Shield of Michigan. MVC's overall aim is to help hospitals and providers in Michigan provide high-quality care at the lowest reasonable cost by working with its member hospitals to advance valuebased initiatives. MVC maintains a claims-based registry that
WHAT IS KNOWN
• Prior work on healthcare value in percutaneous coronary intervention has largely focused on evaluating outcomes and costs.
• Differences in appropriate use have not been explicitly evaluated in the context of variation in outcomes or costs despite its strong conceptual connection with healthcare value.
WHAT THE STUDY ADDS
• 
Study Population
We used iterative deterministic matching to link BMC2 and MVC data to construct a cohort of all Medicare FFS patients (29 839 patients) undergoing PCI from 2010 to 2014 in the State of Michigan (Figure 1 ). We used patient date of birth, sex, procedure dates, and hospital and physician national provider identifiers as the characteristics for indirect matching. MVC identified PCI index cases at hospitals based on hospital diagnosis-related groups on a facility claim or professional claims with current procedural terminology codes for PCI. This comprehensive approach allowed us to capture both inpatient and outpatient PCIs. Once the PCI index case was identified, all clinically relevant claims within 90 days of the procedure date were included in the episode. Overall, 84% of MVC administrative data could be linked to a specific patient within the BMC2 registry. We excluded 3114 PCI episodes for which data were insufficient for calculating appropriate use criteria (AUC) or risk-adjusted mortality. This limitation is owed largely to the fact that 2012 AUC are more comprehensive for classifying acute indications for PCI as compared with stable disease. Future iterations of the AUC may continue to reduce the number of uncertain cases over time, but this is far from certain. 20 We also excluded PCIs performed at 14 hospitals without on-site cardiac surgical backup because of the unique nature of these hospitals and their patients (ie, all PCIs at these hospitals were for emergent indications during this time period).
Measures: Appropriateness, Outcomes, and Costs
We sought to understand the inter-relationships between appropriateness, outcomes, and episode costs based on a novel conceptual framework for healthcare value ( Figure 2 ). In this framework, we consider value to be positively related to better outcomes and more appropriate care at a given level of cost. We performed this analysis at the hospital level to further understand the concept of value as it relates to hospital performance assessments.
For this analysis, we used BMC2 clinical data to calculate appropriateness using the AUC developed by the American College of Cardiology as follows: appropriate (7-9), uncertain (4-6), or inappropriate (1-3). 21 , 22 We used an algorithm previously developed by members of the Clinical Outcomes and Assessment Program and the Northern New England Cardiovascular Disease Study Group to automate calculation of the AUC based on clinical data elements within the BMC2 registry using the 2012 criteria. Details of this algorithm have been previously published. 23 Example scores for 6 different patient scenarios are included in the appendix in the Data Supplement.
Outcomes for 90-day readmission were defined as any admission occurring within 90 days after being discharged alive from the index PCI hospitalization or procedure. We defined 90-day mortality as a death that occurred anytime in the 90 days after index PCI. Longitudinal outcomes were assessed using MVC administrative claims data. 24, 25 Costs were obtained by aggregating insurance payments across an episode of care, which was defined as the time period encompassing the index PCI case and the subsequent 90 days that included all testing, inpatient, and outpatient services delivered during this window. Individual episode payments were classified into 1 of 4 payment categories: (1) index hospitalization, (2) professional services, (3) readmissions, and (4) postacute care (eg, skilled nursing facility, rehabilitation, home health, emergency department visits). Payments were price standardized to eliminate the impact of hospital-specific adjustments (ie, for geographic location, medical education, health information technology adoption) allowing us to measure resource utilization. Price standardization was performed by assigning a standardized payment to each PCI, reflecting the average Medicare payment in Michigan. Episode payments were risk standardized using the following variables: age, sex, 70 comorbidities, and high spending for the prior 6 months as assessed by International Classification of Diseases, Ninth Revision codes at presentation. 26 
Statistical Analysis
We hypothesized that appropriateness is an important dimension of healthcare value that is independent of risk-standardized outcomes and costs.
We calculated and reported AUC scores at the hospital level. AUC scores do not require adjustment because they are specifically designed to create scenarios where clinical risk and benefits are equally evaluated by participating clinicians. Riskstandardized outcomes at the hospital level were obtained using previously developed prediction models where available patient-level characteristics were incorporated as fixed effects in hierarchical mixed effects regression models with a hospital-level random intercept. 27 For the 90-day post-PCI mortality, patient-level risk estimates were obtained from the BMC2 random forest mortality model and included as a fixed effect term in a hierarchical mixed effects regression model with a hospital-level random intercept. [28] [29] [30] For the 90-day readmission measure, initial patient-level risk estimates were obtained using the coefficients previously identified by Center for Medicare and Medicaid Services. 31 Risk-standardized measures at the hospital level were then obtained by multiplying the overall outcome rate observed in the cohort by the ratio of mean predicted to mean expected rate estimates for each site from the fitted mixed effects model, where the expected rate is calculated using the fixed effect fitted coefficients, and the predicted rate incorporates both the fixed effect contribution and the posterior mode of the random intercept estimated using an empirical Bayes algorithm. This allowed for adjustment of both risk and reliability at hospitals with lower PCI volumes.
For standardized episode costs, a hierarchical regression model was fitted adjusting for the index hospitalization diagnosis-related groups, along with comorbidity flags generated from International Classification of Diseases, Ninth Revision diagnostic codes present on the index admission billing record.
We then examined correlations between hospital-level AUC scores with risk-standardized outcomes and costs. Spearman correlation coefficients and scatterplots with superimposed locally weighted scatterplot smoothing curves were used to assess within-site correlation between AUC scores, risk-standardized outcomes, and risk-standardized episode costs. In addition to our overall analyses, we also examined correlations after stratifying patients as to whether or not PCI was performed in the setting of an AMI because previous work has suggested that 98.6% of acute indications for PCI are rated as appropriate.
32
RESULTS
Overall Cohort
From June 30, 2010, to December 31, 2014, 32 953 episodes of PCI were identified in FFS Medicare beneficiaries at 33 hospitals in Michigan. Of these, 29 839 (90.5%) PCIs were successfully mapped to the AUC. Excluded patients (n=3114) were more likely to have presented with stable angina (42.7% versus 9.8%) and a PCI indication of other (63.5% versus 4.7%; ie, not the defined categories for primary PCI, other ST-segment-elevation AMI presentation or high-risk non-STsegment-elevation AMI or unstable angina). The mean number of PCIs performed per hospital was 904, and the median number was 696 during the study period. The baseline characteristics of the entire cohort and 
Hospital-Level Outcomes
At the hospital level, the overall mean AUC score was 8.4±0.2 (range, 7.97-8.79) with the mean proportion of cases identified as appropriate at the hospitals calculated at 91%±3.7%. The mean hospital-level risk-standardized 90-day readmission rate (RSRR) was 23.7%±3.7% (range, 16.1%-30.5%). Common reasons for readmission within 90 days based on the readmission diagnosisrelated group included repeat PCI (20.6%), heart failure (11.9%), gastrointestinal hemorrhage with or without complications (5.7%), and AMI (4.9%). The mean hospital-level risk-standardized 90-day mortality rate (RSMR) was 4.3% (range, 2.9%-5.5%). The mean hospital-level risk-standardized episode costs (RSEC) were $26 159±$1074 (range, $24 287-$29 161). Neither hospital-level AUC scores nor proportions of appropriate cases were associated with RSRR, RSMR, or RSEC (Figures 3-5 ). Higher RSRR were strongly associated with higher RSEC (R, 0.73; P<0.0001). Figure 6 is a 3-dimensional plot that displays the inter-relationships between mean hospital-level AUC scores, RSMR, and RSEC. The plot demonstrates the lack of relationship between hospital-level AUC scores and the other domains of PCI care.
Non-AMI Cohort
We stratified our analysis by the presence of AMI given the important role of this diagnosis in driving appropriateness in the AUC. During the study period, 18 415 patients (61.6%) underwent PCI for a non-AMI indication. In this cohort, the mean hospital-level AUC score was 8.1±0.3, mean RSRR was 23.0%±2.7% (range, 17.5%-28.5%), RSMR was 1.7%±0.3% (range, 1.3%-2.5%), and mean RSEC were $23 918±$1048 (range, $22 434-$25 934). AMI indicates acute myocardial infarction; CABG, coronary artery bypass graft; CAD, coronary artery disease; MI, myocardial infarction; NA, not applicable; PCI, percutaneous coronary intervention; and STEMI, ST-segment-elevation myocardial infarction. Two patients did not have a ACS presentation directly documented in the BMC2 registry using this variable.
Higher RSRR were associated with higher RSMR (R, 0.50; P=0.0038). Higher RSEC were also associated with higher RSRR (R, 0.77; P<0.0001) and RSMR (R, 0.51; P=0.0027). Neither hospital AUC scores nor proportions of appropriate cases were associated with RSRR, RSMR, or RSEC.
AMI Cohort
In this subgroup, 11 424 patients underwent PCI for AMI. The mean AUC score at the hospital level was 8.9±0.1, the RSRR was 24.9%±4.2% (range, 17.6%-33.8%), the RSMR was 8.3%±0.9% (range, 6.2%-11.0%), and RSEC were $29 726±$1362 (range, $27 330-$33 809). Higher RSEC were associated with higher RSRR (R, 0.62; P=0.0002) but not higher RSMR (R, 0.24; P=0.16). Neither mean hospital-level AUC scores nor proportions of appropriate cases were associated with RSRR, RSMR, or RSEC.
DISCUSSION
In this study, we examined the key relationship of appropriateness with outcomes and costs of PCI. Our most important finding was that average AUC scores did not correlate with either 90-day outcomes or episode costs at the hospital level. In contrast and not surprisingly, we found that poor outcomes were associated with higher costs. Taken together, these findings suggest that appropriateness is an independent measure of healthcare value for PCI that needs to be considered separately along with outcomes and costs when assessing the overall performance of the procedure. We are unaware of prior work directly examining AUC scores with these other dimensions of value simultaneously.
Value in healthcare was originally defined as achieved outcomes per unit of cost. 8 However, the morbidity, mortality, and cost burden of inappropriate procedures adds no value to healthcare delivery. Performing a PCI in an asymptomatic patient with a nonobstructive lesion can be done at low cost and mortality but with no expected clinical benefit to the patient. Traditional outcome measures are increasingly a major focus of quality programs, and some may argue that comprehensive outcome measurement may reduce the role of the AUC by encompassing appropriateness. However, we think that appropriateness remains a distinct concept under most current views that attempt to quantify the potential benefit of a particular procedure and the decision making that led to care taking place. In the future, this may change if additional outcomes measurement begins to incorporate the reason behind the procedure into its assessments. For example, if we are able to more comprehensively and reliably measure angina in the future, then these measurements can inform both the appropriateness of the procedure and assessment of its outcomes.
Although improving appropriateness has been the focus of quality efforts, its relationship with episode costs and outcomes has been understudied. Overall, the appropriate use of PCI has been improving nationally, and our findings are consistent with this trend. 33 We found similarly low and declining rates of stable angina consistent with recent contemporary reports. Whether these findings represent improvements in care, changes in documentation, or intentional up-coding of the AUC toward acute coronary syndrome presentations is unknown. Hospital-level variations even at high levels of appropriateness suggest significant variations in care delivery. Appropriateness has been associated with better quality of life and freedom from angina in PCI. 30 Ko et al 12 also found that appropriate use of PCI in patients with stable angina was associated with better outcomes when compared with medical management alone in Ontario. This highlights that improving patient selection in the cases of both underuse and overuse of PCI may improve outcomes. Appropriateness has been examined in the setting of procedural complications within the National Cardiovascular Data Registry. In that study, procedural complications did not correlate with appropriateness, suggesting that the latter represented a distinct aspect of PCI care. 34 Like this prior report from the National Cardiovascular Data Registry, we found no relationship between appropriateness and 90-day outcomes of readmission and mortality.
However, our results differ from prior investigations in the Veterans Affairs Healthcare System. 8, 9 Unlike these studies, we found an association between higher risk-adjusted costs and higher readmissions and mortality. Care delivery at private institutions is subject to significantly different payment structures and incentives when compared with the Veterans Affairs Healthcare System. This may have played a role in this important discrepancy. For example, in the hospitals we studied, poor outcomes because of complications may have led to higher downstream utilization of services and raised costs for payers, in contrast to the Veterans Affairs's integrated delivery system, where these incentives do not exist. Thus, it seems that quality improvement aimed at improving readmissions and longitudinal mortality may have a significant impact on costs in many private hospitals.
Early papers describing value-based healthcare defined it over specific cycles of care. 24 Going a step further and adding the dimension of appropriateness to the definition of value identify downstream episode costs that could be altogether avoided. In our investigation, we chose to define this cycle as 90 days post-procedure because we felt this was a long enough period to capture outcomes and utilization related to the coronary disease presentation treated with PCI. Prior investigations have defined post-PCI cycles of care as short as 1 month and as long as 1 year. 9, 10 These investigations found the majority of PCI cost variation occurs during the index procedure, supporting our decision for using this cycle. Defining the ideal cycle of care in the context of appropriateness has important implications for how best to design bundled payment in PCI and will require additional investigations. 35 It is important to pursue a strategy that encourages appropriate patient selection, postprocedure care coordination, and judicious postprocedure testing.
What are the possible implications of our findings? One key conclusion is that we need to reconsider PCI value in a multidimensional space that includes all relevant components of value ( Figure 6 ). Including appropriateness along with outcomes and costs allows us to consider the extent to which a PCI was of expected clinical benefit when the decision was made to pursue it. For example, when one examines all 3 of these dimensions simultaneously, the benefits of performing highvalue PCI becomes more readily apparent. This makes intuitive sense because some hospitals may perform PCI with low mortality and low costs but in less appropriate patients. The 3 orange hospitals highlighted on this figure ( Figure 6 ) suggest such facilities where specific improvement efforts may be targeted, and the 3 green hospitals identify high performers where best practices can be investigated. This demonstrates the potential to create a PCI value index that may be used to compare the value of PCI across institutions and can also be used to internally monitor quality improvement efforts.
Our study has important limitations. First, it is restricted to FFS Medicare patients in a single state; conclusions about this study population should be extrapolated with caution to national cohorts or other states with different case-mixes of patients. Our results may not reflect the care of patients undergoing PCI by commercial payers both in the elderly (eg, Medicare Advantage programs) and nonelderly. Second, hospitals in this cohort also have been actively participating in a statewide quality collaborative aimed at improving outcomes for over a decade. This could be a reason for the high overall performance, including high rates of appropriateness and low rates of adverse outcomes. A high proportion of the PCIs in our cohort was performed for acute indications, which contributes to overall high hospital-level AUC scores. This high degree of appropriateness limits our ability to evaluate how this characteristic may interact with outcomes and costs at the extremes of lower performance. It also highlights the potential need for better and more refined AUC to better explore this dimension of value. Third, important outcomes that are also critical to the clinical evaluation of nonacute PCI were not assessed, such as angina burden, functional status, or health-related quality of life. Unfortunately, these outcomes are not collected post-procedurally in our registry and are poorly collected in most registries. These and other patient-reported outcomes are critical to capturing the intrinsic healthcare value of PCI care and may also drive assessments of appropriateness. Future work will need to address this specific limitation. Fourth, our data set only contains patients who underwent PCI. We do not have an assessment of other patients during this time period, who were either managed medically or underwent surgical revascularization. Greater detail on revascularization patterns at hospitals may be useful to assessing healthcare value. Finally, we chose to analyze our cohort at the hospital level as we were most interested in understanding PCI value as a hospital-based quality metric. Extrapolation of our findings to individual patients is not recommended because our analysis was not designed to make such conclusions.
Despite these issues, we think our investigation adds significantly to the discussion of healthcare value in PCI. Our findings support the argument that a comprehensive evaluation of healthcare value for PCI must take into account appropriateness. The lack of a relationship between hospital-level appropriateness and outcomes or costs is an important finding, which demonstrates the importance of a new multidimensional conceptual framework for value that can potentially serve as the basis for novel metrics moving forward. By factoring appropriateness into the definition of healthcare value, policy makers and payers may better transition to reimbursing high-value care.
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